Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus

NCT06886919 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Difficult to Treat Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.